AR084886A1 - Proteinas de union a inhibidores de factores de coagulacion - Google Patents

Proteinas de union a inhibidores de factores de coagulacion

Info

Publication number
AR084886A1
AR084886A1 ARP120100166A ARP120100166A AR084886A1 AR 084886 A1 AR084886 A1 AR 084886A1 AR P120100166 A ARP120100166 A AR P120100166A AR P120100166 A ARP120100166 A AR P120100166A AR 084886 A1 AR084886 A1 AR 084886A1
Authority
AR
Argentina
Prior art keywords
seq
presented
cdr sequences
antibody
variable
Prior art date
Application number
ARP120100166A
Other languages
English (en)
Spanish (es)
Inventor
Dittmer Frank Dr
Buchmller Anja Dr
Gerdes Christoph Dr
Tersteegen Adrian Dr
Gnoth Mark Jean Dr
Linden Lars Dr
Harrenga Axel Dr
Grudzinska Joanna Dr
Jeske Mario Dr
Schfer Martina Dr
Birkenfeld Jrg Dr
Paulsen Holger Dr
Finnern Ricarda Dr
Mayer-Bartschmid Anke Dr
Eicker Andrea Dr
Simone Greven
Susanne Steinig
Original Assignee
Bayer Pharma Aktiengellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengellschaft filed Critical Bayer Pharma Aktiengellschaft
Publication of AR084886A1 publication Critical patent/AR084886A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ARP120100166A 2011-01-19 2012-01-18 Proteinas de union a inhibidores de factores de coagulacion AR084886A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11151410 2011-01-19

Publications (1)

Publication Number Publication Date
AR084886A1 true AR084886A1 (es) 2013-07-10

Family

ID=45491612

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100166A AR084886A1 (es) 2011-01-19 2012-01-18 Proteinas de union a inhibidores de factores de coagulacion

Country Status (7)

Country Link
US (1) US20140050743A1 (enExample)
EP (1) EP2665751A1 (enExample)
JP (1) JP2014506448A (enExample)
CN (1) CN103619883A (enExample)
AR (1) AR084886A1 (enExample)
CA (1) CA2824885A1 (enExample)
WO (1) WO2012098089A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3434690A4 (en) * 2016-03-23 2020-04-01 Seoul National University R&DB Foundation ANTIBODY BINDING TO HULL GLYCOPROTEIN OF HEAVY-FEVER-WITH-THROMBOZYTOPENIA-SYNDROME-VIRUS AND THE USE THEREOF
GB201618432D0 (en) 2016-11-01 2016-12-14 Matn Scient Ltd Detection and treatment of demyelinating diseases
KR20190112747A (ko) * 2017-02-01 2019-10-07 노보 노르디스크 에이/에스 응고촉진 항체
NL2036011B1 (en) 2023-10-12 2025-04-30 Synapse Res Institute Molecules for reversing anti-coagulant activity of direct oral anticoagulants

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
ATE311366T1 (de) 2000-02-29 2005-12-15 Millennium Pharm Inc Benzamide und ähnliche inhibitoren vom faktor xa
US6669937B2 (en) * 2000-04-20 2003-12-30 The Board Of Trustees Of The University Of Arkansas Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs
WO2003000657A1 (en) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
ES2389027T3 (es) 2001-06-20 2012-10-22 Daiichi Sankyo Company, Limited Derivados de diamina
RS51444B (sr) 2001-09-21 2011-04-30 Bristol-Myers Squibb Company JEDINJENJA KOJA SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa
DE102007028320A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
EP3824902A1 (en) 2007-09-28 2021-05-26 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
CN102316893B (zh) * 2008-11-14 2015-02-18 博尔托拉制药公司 因子Xa抑制剂的解毒剂及其与血液凝固剂组合使用的方法
AR079944A1 (es) * 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante

Also Published As

Publication number Publication date
CN103619883A (zh) 2014-03-05
US20140050743A1 (en) 2014-02-20
JP2014506448A (ja) 2014-03-17
WO2012098089A1 (en) 2012-07-26
CA2824885A1 (en) 2012-07-26
EP2665751A1 (en) 2013-11-27

Similar Documents

Publication Publication Date Title
AR087567A1 (es) Anticuerpos anti-tie2 y usos de los mismos
MX363642B (es) Metodos para reducir los niveles de lipoproteina (a) administrando un inhibidor de proproteina convertasa subtilisina kexina-9 (pcsk9).
UY33196A (es) Antidotos de anticoagulantes
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
AR092005A1 (es) Anticuerpos anti-pcsk9 y uso de los mismos
NZ706377A (en) Il-6 antagonists and uses thereof
CO6260094A2 (es) Anticuerpos novedosos anti-alpha5beta1 y usos de los mismos
EP2532365A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
EP2532366A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER
CY1119994T1 (el) Συνθεσεις και μεθοδοι για αυξηση της μυϊκης μαζας και της μυϊκης δυναμης ανταγωνιζοντας ειδικα ton gdf8 και/ή την ακτιβινη α
RU2012143793A (ru) Биспецифические двухвалентные антитела анти-vegf/анти-ang-2
AR083747A1 (es) Anticuerpos anti-il-23
EA201490825A1 (ru) Tdp-43-специфически связывающие молекулы
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
EA201491569A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
ECSP17005649A (es) Anticuerpos anti-tau humanizados
AR094141A1 (es) Composiciones y metodos para proteinas de accion prolongada
BR112014011331A2 (pt) anticorpos específicos para trop-2 e seus usos
AR095432A1 (es) Proteínas de unión a antígeno
AR065420A1 (es) Anticuerpos anti-il-23 p19 de ingenieria
EA201400568A1 (ru) Альбуминсвязывающие антитела и их связывающие фрагменты
BR112015029953A2 (pt) anticorpos anti-tweakr e seus usos
MX369276B (es) Agentes para tratamiento de enfermedades cancerosas que expresan claudina.
AR093394A1 (es) Anticuerpos especificos del factor de crecimiento b derivado de plaquetas (pdgf-b), composiciones y usos de estos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal